| Active substance | abrocitinib |
| Holder | Pfizer NV/SA |
| Status | Running |
| Indication | the treatment of adolescents (12-17 years old) with severe atopic dermatitis or who have participated to the Abrocitinib Expanded access JADE REAL – B7451064 with EudraCT reference 2020-003610-12. |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 23/04/2024 |